Intellia TherapeuticsNTLA

The FDA has accepted Intellia’s application for lonvo-z, a treatment for hereditary angioedema, a rare condition that causes severe and unpredictable swelling. The agency granted it priority review, which shortens the evaluation time because the drug could offer a major improvement over current options. If approved, it would be the first CRISPR therapy to work by editing genes directly inside a patient’s body with a single infusion.

This is a critical milestone for Intellia’s transition from a research firm to a commercial drugmaker. A March 2027 approval would not only provide a one-time treatment for patients who currently rely on lifelong injections, but it would also validate Intellia’s entire technology platform. Success here would prove that systemic gene editing is safe and effective enough for broad regulatory clearance.

Source: GlobeNewsWire

SEC filing on 2026-09-04: 8-K, 8-K filing: entered a material agreement; took on new debt or obligations; Regulation FD disclosure.

What the filing says (its own text, every fact in the card must come from here, and NAME the specific person, role and date it gives): 8-K false 0001652130 GB 0001652130 2026-09-04 2026-09-04 0001652130 dei:FormerAddressMember 2026-09-04 2026-09-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2026 INTELLIA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37766 36-4785571 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 400 Technology Square , Suite 100 Cambridge , Massachusetts 02139 (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Number, Including Area Code: ( 857 ) 285-6200 40 Erie Street , Suite 130 , Cambridge , Massachusetts 02139 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock (Par Value $0.0001) NTLA The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 1.01. Entry into a Material Definitive Agreement. On September 4, 2026 (the "Closing Date"), Intellia Therapeutics, Inc. (the "Company" or "Intellia") entered into a Credit Agreement (the "Credit Agreement") with the lenders from time to time party thereto ("Lenders"), and OrbiMed Royalty & Credit Opportunities V, LP, as administrative agent ("Administrative Agent"). OrbiMed Royalty & Credit Opportunities IV, LP, and OrbiMed Royalty & Credit Opportunities V, LP, are the initial Lenders. The Credit Agreement provides the Company with a five-year senior secured credit facility of up to $400 million (the "Credit Facility"), available in the following tranches: (1) $75 million drawn on the Closing Date, (2) a potential additional $75 million draw at the Company's option upon the approval by the U.S. Food and Drug Administration ("FDA") of the Company's biologics license application ("BLA") for lonvoguran ziclumeran ("lonvo-z") prior to a certain date, (3) three potential additional $40 million draws at the Company's option upon achieving certain revenue targets for lonvo-z prior to certain dates, (4) a potential additional $30 million draw at the Company's option upon achieving an equity fundraising target prior to a certain date, and (5) an uncommitted additional incremental facility up to $100 million subject to mutual agreement among the Company and the Lenders. The proceeds of the Credit Facility will be used for the working capital needs and general corporate purposes of the Company. The Credit Facility matures on September 4, 2031 (the "Maturity Date"), and the entire then-outstanding principal amount of the loans will be due on the Maturity Date. Loans outstanding under the Credit Facility bear interest, payable monthly, at a rate per annum equal to (1) the greater of (a) 3.00% or (b) the one-month SOFR rate applicable to such period plus (2) an applicable margin of 6.15%. In addition, the Company is required to pay certain customary commitment, administrative, undrawn amount and facility fees in connection with the Credit Facility. The Company may elect to prepay all or any portion of the amounts owed prior to the Maturity Date subject to a repayment premium or exit fee, as applicable, as well as from accrued interest on the principal amount repaid or prepaid. The Credit Facility is also subject to customary mandatory prepayments with the proceeds of indebtedness and certain asset sales and casualty events. All obligations under the Credit Agreement are secured on a first-priority basis, subject to certain exceptions, by security interests in substantially all assets of the Company, including its intellectual property. In addition, the Credit Agreement contains customary covenants, including, without limitation, (i) financial covenants to (1) maintain liquidity of at least $50 million in controlled accounts until the FDA approves the BLA for lonvo-z and (2) either achieve certain revenue targets, maintain certain market capitalization thresholds or maintain the outstanding loan principal in cash equivalents in controlled accounts, and (ii) negative covenants that, subject to certain exceptions, restrict the Company's ability to incur additional indebtedness, grant liens, make investments (including acquisitions), effectuate mergers or consolidations, engage in asset sales and licensing transactions, pay dividends, terminate or modify certain material agreements, pay subordinated indebtedness, and undertake other matters customarily restricted in such agreements. The exceptions to incurring additional indebtedness and granting liens include an exception allowing the Company to enter synthetic royalty transactions, subject to certain restrictions in the Credit Agreement. The Credit Agreement also contains certain events of default after which loans under the Credit Facility ma

Source: 8-K filing

Evercore ISI, a widely followed investment firm, upgraded its view on the stock to outperform. This is their highest rating and suggests they expect the company to do better than the broader market.

The move comes as the company works to turn its successful clinical trials into the first-ever approved CRISPR drugs that edit genes directly inside a patient's body. While the stock has been volatile, this upgrade reflects growing confidence that the company can navigate the final regulatory steps and transition into a commercial drugmaker.

Intellia reported its second quarter financial results, which show a business in transition from a research lab to a commercial drugmaker. The company is currently working toward its first-ever regulatory approval for a CRISPR therapy, a tool that allows scientists to precisely edit DNA to treat genetic diseases.

Because the company does not yet have a drug on the market, it still relies on cash reserves and partnerships to fund its work. The focus for long-term owners remains on the 2027 launch timeline and the company's ability to manage its cash, which it previously stated should last into 2028. This quarter confirms that the business is staying on that track as it builds out the manufacturing and sales teams needed to support its first approved medicine.

Source: GlobeNewsWire